文献速递胸部肿瘤

肺癌放疗联合抗PD-1/PD-L1:构建更好的转化研究平台

Radiotherapy and anti-PD-1/PD-L1 combinations in lung cancer: building better translational research platforms.
PubMed 文献 · Ann Oncol · 2018-01-01

本文综述非小细胞肺癌(NSCLC)中抗PD-1/PD-L1耐药原因及放疗联合免疫检查点阻断的潜在机制。放疗可诱导免疫原性改变、上调肿瘤细胞PD-L1表达并改善抗PD-1/PD-L1疗效。未来临床试验设计需考虑放疗剂量、分割、照射野体积及与免疫检查点阻断的时序安排。

要点

  • 放疗可诱导免疫原性改变并上调肿瘤PD-L1,改善抗PD-1/PD-L1疗效。
  • NSCLC中PD-L1表达和瘤内T细胞浸润与抗PD-1/PD-L1临床获益相关。
  • 联合试验设计需考虑放疗剂量、分割、照射野体积及与免疫治疗时序。

核心结论

  • 放疗联合抗PD-1/PD-L1是改善NSCLC免疫检查点阻断应答率的潜在策略。

研究设计与样本

  • 综述,未报告系统检索范围与样本量。

主要发现

  • PD-L1肿瘤表达和预存肿瘤T细胞浸润与抗PD-1/抗PD-L1改善的临床结局相关。
  • PD-L1表达阴性肿瘤患者也可对抗PD-1/抗PD-L1治疗应答。
  • 放疗诱导癌细胞免疫原性改变,可适应性上调肿瘤细胞PD-L1表达,并可改善抗PD-1/抗PD-L1疗效。

临床怎么用

  • 未来NSCLC临床试验设计需考虑放疗剂量、分割和照射野体积,以及与免疫检查点阻断的时序安排。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite the unheralded success of immune checkpoint blockade in delivering durable responses for some patients with non-small-cell lung cancer (NSCLC), the majority of patients do not respond. PD-L1 tumour expression and pre-existing tumour T-cell infiltration have been correlated with improved clinical outcomes to anti-PD-1/anti-PD-L1. However, patients with tumours that are negative for PD-L1 expression can also respond to treatment. Strategies to combine other treatment modalities like radiotherapy (RT) with immune checkpoint inhibitors are being investigated as means of improving the response rates to PD-1/PD-L1 antibody blockade. RT induces immunogenic changes in cancer cells, can adaptively upregulate tumour cell PD-L1 expression and can improve the efficacy of anti-PD-1/anti-PD-L1 therapy. How we design future clinical trials in NSCLC also depends on practical considerations of delivering these treatment combinations, such as RT dose, fractionation and field volume, as well as scheduling with immune checkpoint blockade. Here, we review reasons for resistance to anti-PD-1/anti-PD-L1 and how RT may be utilised in combination with these drugs to enhance their effect by building better translational research platforms.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Kordbacheh T, Honeychurch J, Blackhall F, et al. Radiotherapy and anti-PD-1/PD-L1 combinations in lung cancer: building better translational research platforms. Ann Oncol. 2018. PMID: 29309540. doi:10.1093/annonc/mdx790

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。